Practical Guide to Implementing Liquid Chromatography Mass Spectrometry in Clinical Laboratories

Y. Victoria Zhang
Uttam Garg
Editors

Springer

Practical Guide to Implementing Liquid Chromatography Mass Spectrometry in Clinical Laboratories

Y. Victoria Zhang • Uttam Garg
Editors

Practical Guide to Implementing Liquid Chromatography Mass Spectrometry in Clinical Laboratories

Springer

Editors
Y. Victoria Zhang
Pathology and Laboratory Medicine
University of Rochester Medical Center
Rochester, NY, USA

Uttam Garg
Pathology and Laboratory Medicine
Children's Mercy Hospital and University of Missouri-Kansas City School of Medicine
Kansas City, MO, USA

ISBN 978-3-032-03851-7 ISBN 978-3-032-03852-4 (eBook)
https://doi.org/10.1007/978-3-032-03852-4

This Springer imprint is published by the registered company Springer Nature Switzerland AG
The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland

Preface

Mass spectrometry coupled with liquid chromatography has long been a cornerstone of research laboratories, but its migration into the clinical setting marks one of the most transformative shifts in modern laboratory medicine. The ability of liquid chromatography–tandem mass spectrometry (LC-MS/MS) to provide highly specific, sensitive, and multiplexed analyses has opened new frontiers in diagnostics—from therapeutic drug monitoring to endocrinology, toxicology, and beyond. Yet for many clinical laboratories, the transition from theoretical interest to practical implementation remains challenging.

This book was designed to bridge that gap.

Practical Guide to Implementing Liquid Chromatography Mass Spectrometry in Clinical Laboratories was developed to provide a clear and structured roadmap for laboratories looking to implement or expand LC-MS/MS technologies. Whether you are a medical technologist building your first assay, a pathologist overseeing validation, or a laboratory director shaping long-term strategy, this guide aims to offer relevant and practical insights at every step.

The chapters walk through foundational principles, instrumentation considerations, method development and validation, sample preparation, troubleshooting, quality assurance, regulatory expectations, and real-world clinical applications. A dedicated chapter at the end of the book includes multiple-choice questions based on each chapter, designed to reinforce key concepts and support teaching, training, and self-assessment.

The authors have drawn from their collective experience across academic medical centers, hospital systems, and reference laboratories. We hope the lessons, tools, and practical advice shared in these pages empower laboratory professionals to embrace mass spectrometry with confidence and purpose.

Above all, we hope this book serves not only as a technical manual but also as a catalyst to inspire laboratories to advance diagnostic science and improve patient care through thoughtful, rigorous implementation of liquid chromatography mass spectrometry in clinical laboratories.

Rochester, NY, USA — Y. Victoria Zhang
Kansas City, MO, USA — Uttam Garg

Contents

Introduction to Implementation of LC-MS/MS in Clinical Laboratory

1

Uttam Garg, Alan L. Rockwood, David Herold, and Y. Victoria Zhang

Brief History of Liquid Chromatography and Mass Spectrometry

Liquid chromatography (LC) and mass spectrometry (MS) have become indispensable analytical techniques across various scientific disciplines, including pharmaceutical development, proteomics, environmental analysis, and clinical diagnostics. The integration of LC and MS has revolutionized modern analytical workflows, enabling highly sensitive and specific detection of complex biological and chemical samples, particularly for clinical applications.

The origins of LC date back to 1903, when Mikhail Tswett introduced adsorption chromatography to separate plant pigments [1]. Over the following decades, key advancements—including partition chromatography, paper chromatography, and

U. Garg
Pathology and Laboratory Medicine, Children's Mercy Hospital and University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA
e-mail: ugarg@cmh.edu

A. L. Rockwood
Emeritus Professor (Clinical) of Pathology, University of Utah School of Medicine, Salt Lake City, UT, USA
e-mail: alan@rockwood-scientific-consulting.com

D. Herold
Department of Pathology, University of California, San Diego, CA, USA

VA Healthcare System, San Diego, CA, USA
e-mail: dherold@ucsd.edu

Y. V. Zhang (✉)
Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA
e-mail: Victoria_Zhang@URMC.Rochester.edu

Y. V. Zhang, U. Garg (eds.), *Practical Guide to Implementing Liquid Chromatography Mass Spectrometry in Clinical Laboratories*,
https://doi.org/10.1007/978-3-032-03852-4_1

gel permeation chromatography—laid the foundation for modern liquid-phase separations [2, 3]. A major breakthrough occurred in the 1960s, and Csaba Horváth and Seymour Lipsky developed high-performance liquid chromatography (HPLC) [4]. Subsequent innovations, including reverse-phase HPLC (RP-HPLC) in the 1970s, capillary LC in the 1980s, and ultra-high-performance liquid chromatography (UHPLC) in the 1990s, further enhanced the technique's capabilities [5–9].

In parallel, MS has undergone significant technological advancements since its inception by J. J. Thomson in 1912, when he first demonstrated the separation of charged particles based on their mass-to-charge ratio (m/z) [10, 11]. FW Aston improved the resolution of mass spectrometry for isotopic analysis and he was awarded the 1922 Nobel Prize in Chemistry [10, 12, 13]. The mid-twentieth century saw major breakthroughs that improved mass resolution and separation capabilities, including the development of time-of-flight (TOF) MS, quadrupole mass analyzers, and ion trapping techniques [14–19]. These innovations, particularly the triple quadrupole analyzer, became essential for clinical diagnostics.

The development of new ionization methods expanded MS applications in biological analysis. Soft ionization techniques introduced in the 1980s and 1990s were of particular significance. Electrospray ionization (ESI), developed by John Fenn, and matrix-assisted laser desorption/ionization (MALDI), developed by Koichi Tanaka, Franz Hillenkamp, and Michael Karas, enabled the analysis of large biomolecules, revolutionizing proteomics, metabolomics, and clinical diagnostics [20–25]. Fenn and Tanaka were awarded the 2002 Nobel Prize in Chemistry for their contributions. The continuous advancement of tandem mass spectrometry (MS/MS), ion trap technologies, and high-resolution MS analyzers has further solidified MS as a cornerstone of modern analytical science.

One of the earlier clinical applications of MS was newborn errors of metabolism screening from dried blood spots [26, 27]. By quantifying amino acids, organic acids, and acylcarnitines, the MS platform allowed for the diagnosis of inherited metabolic disorders of amino acids, organic acids, and fatty acid oxidation disorders such as phenylketonuria (PKU), maple syrup urine disease (MSUD), propionic acidemia, and medium-chain acyl-CoA dehydrogenase (MCAD) deficiency. Early detection of inherited metabolic disorders enabled prompt medical intervention, improving patient outcomes.

By the late twentieth century, LC was successfully coupled with MS, combining the separation power of chromatography with the high sensitivity and specificity of mass spectrometry [28, 29]. This integration has transformed forensic science, environmental analysis, and clinical diagnostics, enabling unprecedented analytical performance.

Applications of LC-MS/MS in Clinical Diagnostics

The adoption of LC-tandem mass spectrometry (LC-MS/MS) in clinical laboratories has significantly enhanced diagnostic capabilities by providing accurate, precise, and highly specific measurements of a wide range of analytes for clinical diagnostics, toxicology, and therapeutic drug monitoring purposes.

LC-MS/MS has revolutionized drug of abuse testing by offering high sensitivity and specificity confirmatory testing for detecting a broad range of illicit and prescription drugs that traditional immunoassays were not able to. Its high specificity has established LC-MS/MS as the gold standard for forensic and clinical toxicology testing. It is widely used for detecting opioids, cannabinoids, amphetamines, benzodiazepines, and other substances in various biological matrices such as urine, blood, oral fluid, and meconium [30–34].

Another major clinical application is therapeutic drug monitoring (TDM), where LC-MS/MS is used to measure drug concentrations in patient samples to ensure optimal drug dosing and prevent toxicity [35–37]. Some examples include immunosuppressant drugs, antiepileptics, and certain antibiotics.

In endocrinology, LC-MS/MS has become the preferred method for measuring steroid hormones again due to its high specificity to be able to distinguish structurally similar steroids [38–40]. Some examples include cortisol, testosterone, 17-hydroxyprogesterone, estradiol, and other steroid hormones and particularly in patient populations that have lower concentrations than the traditional immunoassay detection limit.

The evolution of LC-MS/MS has enabled both targeted and non-targeted analysis of complex body fluid samples. The technique continues to expand its role in clinical diagnostics, providing reliable solutions for a broad range of medical conditions.

Developing LC-MS/MS assays for clinical use requires extensive time and collaboration among scientists. We use the testosterone assay as an example to illustrate the evolution of analytical methods over time.

Historically, testosterone measurement relied on immunoassays, which were prone to interference, especially at low concentrations. Advancing alternative technologies became necessary to ensure accurate and precise testosterone measurements, minimizing interferences that could significantly impact validity testing in women and children.

In 1970, Siekmann et al. [41] reported a mass fragmentographic determination and quantification of testosterone without an internal standard. Chapman [42] later commented that it is advisable to use an internal standard that can be tracked in mass fragmentographic recordings. In 1974, Dehennin et al. [43] introduced a GC method using 4-methyl-19-nortestosterone as an internal standard, which completely separated from testosterone. Chapman [42] later noted that this approach might be disadvantageous since the ions from the two compounds are not detected simultaneously. That same year, Chapman and Bailey [42] reported a method for analyzing testosterone in male plasma spiked with a deuterium-labeled internal standard. While the method was precise and accurate at higher concentrations, it lacked reliability at lower concentrations due to the internal standard's impurity, limiting its usefulness for women and children.

In 1975, Björkhem et al. [44] developed a method using radioactive testosterone as an internal standard. The assay involved multiple steps, including ether extraction, thin-layer chromatography purification, further extraction with methanol, and derivatization. The amounts of unlabeled and labeled testosterone were analyzed at

m/z 432 and 434, respectively. The method demonstrated a standard deviation of approximately 2.7% with a strong correlation (r = 0.83) to a radioimmunoassay. However, Björkhem noted that, as expected, the mass spectrometry method yielded significantly lower values than the radioimmunoassay, likely due to cross-reactivity with dihydrotestosterone and possibly other compounds. In 1979, Siekmann [45] reported a refined workflow utilizing ^{14}C-labeled testosterone as an internal standard. After several preparation steps, the assay used m/z 680 relative to m/z 682 to monitor the unlabeled and ^{14}C-labeled testosterone. The reported lower limit of detection was 10.4 nmol/L (300 ng/dL), with a precision of 1% based on two analyses.

In 1981, Finlay and Gaskell [46] presented a highly specific GC–MS method using [^{2}H] testosterone and unlabeled 17-epitestosterone as internal standards, along with multiple sample preparation and derivatization steps. Their findings indicated that routine immunoassays often overestimate testosterone concentrations, as demonstrated by consistently higher mean values compared to GC–MS results. Despite the strong correlation between the methods (r = 0.997), the discrepancy suggested potential immune-cross-reactivity issues. This work highlighted the sensitivity and specificity advantages of GC–MS as a reference method for evaluating the performance of routine steroid hormone assays. However, the method was not adopted for clinical laboratory use due to the high cost and complexity of the instrumentation. Additionally, it was limited to male subjects and required 10 mL of serum due to sensitivity constraints.

Subsequent methods improved sensitivity through deuterated labeling. Salerno et al. [47] reported a method with a limit of quantification (LOQ) of 1 ng/dL and an intra-assay precision of 7.4% (n = 5). Furuta et al. [48] and Legrand et al. [49] demonstrated good accuracy at higher concentrations, but broad-range quantification across clinically relevant levels remained a challenge.

In 1996, Fitzgerald and Herold [50] developed an electron capture negative chemical ionization GC-MS procedure involving liquid–liquid extraction of serum samples and the synthesis of a pentafluorobenzyloxime/silyl ether derivative of testosterone, which exhibited excellent chromatographic and electron-capturing properties. This assay successfully quantified serum testosterone in the clinically relevant range of 0.69–69.3 nmol/L (20–2000 ng/dL).

This publication sparked discussions and debates regarding the cost-effectiveness of mass spectrometry compared to the accuracy of radioimmunoassay [51–55]. These questions were resolved when commercially available immunoassays were shown to produce inconsistent and often unreliable results, particularly at the low testosterone concentrations observed in women and children. In a comprehensive evaluation by Taieb et al. [56] ten different testosterone immunoassays were compared with ID-GC/MS. The findings revealed that seven of the ten immunoassays overestimated testosterone levels in women, while most immunoassays underestimated these levels in men. These discrepancies highlight the limitations of traditional immunoassays, which do not always ensure the accuracy required for proper diagnostic and therapeutic decisions.

Taieb et al.'s report led to an editorial by Herold and Fitzgerald [57], who critiqued the efficacy of testosterone immunoassays for female patients. Citing Taieb et al.'s study, they argued that the measured values were frequently inaccurate, with deviations so substantial that they were rendered practically meaningless. Their analysis suggested that estimating testosterone levels would be nearly as accurate and significantly more cost-effective. They expressed concerns about the implications for epidemiologic research and advocated for the adoption of mass spectrometry techniques, which have demonstrated superior accuracy in measuring low-abundance steroids in clinical specimens from women.

The ongoing debate over the reliability of testosterone assays underscores the need to select appropriate and validated methods for both clinical and research applications. The future of testosterone measurement lies in the continued advancement and validation of mass spectrometry as a reference method, ensuring precise and reliable data across diverse patient populations.

Analytes Measured by LC-MS/MS

Mass spectrometry is a versatile analytical technique that can be used to measure a wide variety of analytes. Analytes that are measured by MS are typically categorized into two broad groups: small molecules and larger molecules.

Based on clinical utility, small molecules analyzed by mass spectrometry fall into two broad categories: exogenous and endogenous compounds. Exogenous compounds include therapeutic drugs and their metabolites, drugs of abuse, environmental toxins such as pesticides and volatile compounds. Small endogenous compounds include certain hormones, amino acids, organic acids, fatty acids, vitamins and cofactors, neurotransmitters, and bile acids. Commonly measured small molecules in a clinical laboratory are listed in Tables 1.1 and 1.2.

Similarly, large molecules analyzed by mass spectrometry can be divided into two broad categories: exogenous and endogenous compounds. Exogenous large molecules typically include therapeutic agents such as antibodies and peptide hormones. Endogenous compounds include peptide hormones, tumor markers, and other proteins. Commonly measured large molecules in a clinical laboratory are listed in Table 1.3.

Considerations for Implementing LC-MS/MS

The application of LC-tandem mass spectrometry (LC-MS/MS) is rightly hailed as a great advance for laboratory medicine. However, no analytical technique is perfect, and this also applies to diagnostic analyses that are used for patient care. This is because not only are there difficulties, uncertainties, and limitations on the analytical side, but the interpretation of analytical results can sometimes be compounded by uncertainties in how the analytical results are to be interpreted for

Table 1.1 Examples of exogenous small molecules measured by MS

Category	Examples
Therapeutic drugs	
Antibacterial	Sulfonamides, Trimethoprim
Anticoagulants	Dabigatran, Rivaroxaban, Apixaban, Warfarin
Anticonvulsants	Lamotrigine, Levetiracetam, 10-Hydroxycarbazepine, Topiramate, Zonisamide
Antidepressants	Tricyclics and Selective Serotonin Reuptake Inhibitors
Antifungals	Fluconazole, Ketoconazole, Voriconazole
Antihypertensives	Atenolol, Clonidine, Diltiazem, Labetalol, Verapamil
Antineoplastic drugs	Busulfan, Mercaptopurine and Metabolites, Methotrexate
Antipsychotics	Haloperidol, Fluphenazine, Perphenazine, Thiothixene
Antiviral	Acyclovir, Ganciclovir
Cardiac drugs	Flecainide, Mexiletine, Propafenone, Amiodarone
Immunosuppressants	Cyclosporine, Everolimus, Mycophenolic Acid, Sirolimus, Tacrolimus
Drugs of abuse	
Cannabinoids	Natural and Synthetic Cannabinoids such as K2, K3, JWH-018, JWH-073
Opioids	Natural and Synthetic Opioids such as Fentanyl, Acetylfentanyl, Carfentanil, Furanylfentanyl, U-47700, Nitazenes
Sedatives and hypnotics	Barbiturates and Benzodiazepines including Synthetics such as Etizolam, Flubromazolam, Diclazepam
Stimulants	Amphetamines (including synthetic such as MDMA), Cathinones (Methylenedioxypyrovalerone, Mephedrone, Methylone), Cocaine and Metabolites, NBOMe compounds

Table 1.2 Examples of endogenous small molecules measured by MS

Category	Examples
Acylcarnitines	Short, Medium and Long-Chain acylcarnitine
Amino Acids	Tyrosine, Glycine, Cystine, Phenylalanine, Homocystine, Leucine, Isoleucine, Valine, Methionine, Citrulline, Argininosuccinic Acid
Bile Acids	Cholic Acid, Chenodeoxycholic Acid, 7-Hydroxy-4-cholesten-3-one
Hormones	Testosterone, Aldosterone, 17-Hydroxyprogesterone, Androstenedione, Dehydroepiandrosterone, T4, T3
Neurotransmitters	Serotonin, Homovanillic acid, Methyl-Dopa
Organic Acids	Methylmalonic acid, Propionic Acid, Isovaleric Acid, Glutaric Acid
Vitamins and Cofactors	Vitamin D, Cobalamin (B12), Folate, Biotin, B6, Biopterin
Other	Creatine, Guanidinoacetate, Purines, Pyrimidines

patient care. There are numerous considerations to properly implement the platform in a clinical setting to serve patient needs.

From a technical viewpoint, the biggest advantage of LC-MS/MS is the very high degree of analytical specificity. Such high specificity can sometimes be a double-edged sword. For example, it may happen that two related compounds may be diagnostically relevant, but one may be detected in an MS-based assay while the

Table 1.3 Examples of large molecules measured by MS

Category	Examples
Hormones	Insulin, Parathyroid hormone (PTH)
Endogenous Proteins	Thyroglobulin, Hormone-Binding Globulin (SHBG), PTH-like protein, C-peptide, Albumin, Antibodies
Exogenous Proteins	Therapeutic antibodies, Insulin analogues, Vaccines, Bacterial Proteins, Viral Proteins

other may not because of the high analytical specificity of an LC-MS/MS method. This needs to be seriously considered during the assay development phase. A close interaction is required during the method development stage between the person on the diagnostic side of the method and the laboratory professional on the analytical side of the method.

25-OH Vitamin D assay is a great example where 25-OH Vitamin D_2 and 25-OH Vitamin D_3 are clinically important compounds and both should be measured. The way around this issue in the case of vitamin D is to design an LC-MS/MS method to measure the concentration of both analytes. This is technically fairly straightforward, as these compounds can be easily separated by LC. As with any human interaction, there is a possibility of miscommunication, and this could lead to the development of an inappropriate assay.

This issue of inadvertently missing a diagnostically relevant target may be more serious when one enters the realm of protein and peptide analysis (hereafter simply referred to as peptide analysis) because one must consider how to deal with both known and unknown peptide variants.

A successful LC-MS/MS method must target the "correct" *m/z* for the precursor ion. However, if a patient has a peptide sequence variant then the sequence variant is very likely to have a different mass, in which case the peptide is unlikely to be detected, possibly leading to an incorrect analysis and faulty interpretation of the patient's condition (unless the LC/MS–MS method is specifically designed to include the variant(s)).

This is complicated by the fact that a peptide is normally coded by two DNA strands, and unless a mutation occurs on both strands, then at least one of the peptides will have the expected mass, in which case one might expect the measured concentration to be approximately half of the total (normal plus variant) concentration.

A further complication depends on whether the variant form is biologically active or not. In addition, by the fact that not all sequence variants are necessarily known, if an unknown variant occurs, it is likely to be missed altogether. If the variant is from a form that is also active, then detecting only half of the peptide (or protein) may lead to an interpretation that the concentration is outside of the reference interval for the analyte, possibly leading to a faulty medical interpretation.

Another consideration is to avoid over-enthusiastic advocates of mass spectrometry, as there can be a temptation to unfairly denigrate more traditional methods used in the clinical chemistry lab, such as immunoassays. This consideration will

ensure the labs to take best advantage of mass spectrometry and other analytical platforms for patient needs.

Testosterone is a case in point. LC-MS/MS has become a preferred method for the analysis of testosterone in patients who have low levels of testosterone in the blood, especially women and children. This application was to overcome the limitation of immunoassay at low concentrations for accurate results. However, an immunoassay is perfectly fine for patients such as male patients with high testosterone levels.

Another consideration of implementing mass spectrometry relates to cost. Mass spectrometry is often considered as a low-cost approach for day-to-day sample analysis due to its generic and low-cost consumables. However, the initial instrument capital cost is significant and so is the staffing requirements to develop the assay in assay and to operate the platform.

This points to a good strategy on how to use mass spectrometry in the clinical lab, which is to apply MS to problems that either have no other well-established solution or for which mass spectrometry provides a much better solution than other methods. For example, an important early driver for the adoption of mass spectrometry was the immunosuppressant drug sirolimus. When it was approved for patient use, there was no FDA approved method for this drug, so laboratories looked for other technologies to use as a basis for a laboratory-developed test. LC-MS/MS turned out to be very well suited for this task, and this in turn led to the application of MS for other immunosuppressant drugs, such as tacrolimus and others. Often, these analytes were combined into a single LC-MS/MS method, which in some ways can simplify the logistics of dealing with this class of drugs.

The “care and feeding” of mass spectrometers is also a challenge that needs to be considered. In particular, a good maintenance and servicing system is essential for a smooth-running lab, and because these instruments are generally not supplied by traditional vendors of clinical laboratory equipment, the laboratory will not be able to rely on those sources of maintenance and service. They will either have to depend on mass spectrometry vendors for those services, or third-party support, or they will need to develop those skills in-house, which usually means staff persons who are dedicated to those tasks rather than being directly involved in the day-to-day testing of patient samples. There is another issue that needs to be considered, and that is that mass spectrometers are inherently serial devices. Multiplexing technologies have made significant progress in the past decade, though the overall throughput is still limited.

In general, though a very powerful platform, implementing LC-MS/MS in the clinical laboratories has numerous considerations. A great deal of expertise and experience are needed to take the full advantage of LC-MS/MS to best serve clinical and patient needs. To advance the use of mass spectrometry in clinical diagnostics, several programs and organizations have emerged in the past couple of decades. In this regard, the 2007 Asilomar conference played a key role in the establishment of the Association for Mass Spectrometry & Advances in the Clinical Lab (MSACL) in 2009. Later, in 2013, the Association for Diagnostics & Laboratory Medicine (ADLM) created the mass spectrometry and separation sciences (MSSS) division.

These groups have collaborated to promote the applications of mass spectrometry platforms in clinical diagnostics for the betterment of patient care.

Looking to the Future

We can expect to see a greater degree of automation for methods that are LDTs. It also applies to a new class of products on the horizon, dedicated automated clinical mass spectrometers that operate much like automated analyzers typically found in core labs, except samples are prepared in a manner compatible with mass spectrometry, and mass spectrometers are used as detection devices [58–61]. It is to be anticipated that such instruments, and the methods targeted by those instruments, will go through FDA approval at the vendor level.

We can expect to see an expanded role for mass spectrometry in the analysis of biopolymers, particularly proteins and peptides. In the earliest stages, we can expect the analytical targets to be analytes that are well established, for which mass spectrometers provide an alternative means of analysis. This process has already started with mass spectrometry taking the place of immunoassays, either in part or in whole, for analytes such as thyroglobulin.

In other cases, proof-of-principle studies have been done using mass spectrometry to replace other means of analysis, an example being analysis of hemoglobinopathies and A1c. Although these capabilities have been shown in proof of principle R&D studies, widespread uptake is yet to occur.

In the more distant future, we may see newly discovered analytical targets that are brought into clinical practice using mass spectrometry analysis. Discoveries in "omics" fields (proteomics, metabolomics, lipidomics, etc.) come to mind. Interestingly, discovery studies in proteomics and metabolomics often make heavy use of mass spectrometry. So far, "omics" has had very little impact on diagnostics used for patient care because few, if any, omics-based discoveries have actually made their way into clinical diagnostic laboratories, but one can expect this to change in the future.

DNA/RNA are wild cards with more uncertain futures when it comes to the use of mass spectrometry for routine clinical analysis because it is hard to identify how mass spectrometry brings essential capabilities to the table that are not already met by other technologies, but only the future will tell.

Triple quadrupole mass spectrometry has so far dominated in the use of mass spectrometers for clinical applications. However, several other technologies provide advantages that may be useful in certain cases. Without going into details, a few examples include time-of-flight mass spectrometers (TOF), high-resolution mass spectrometry, quadrupole time-of-flight mass spectrometers, Fourier transform ion cyclotron resonance mass spectrometers, and Orbitrap mass spectrometers. These technologies may include advantages in higher throughput, multi-analyte analysis, higher resolution, or higher mass accuracy, depending on what technology is under consideration.

Point-of-care mass spectrometry may also have a future, and particularly as miniaturized mass spectrometers are being developed at several laboratories. These have the potential to be placed closer to the patient rather than at more distant centralized laboratories. An obvious application would be to use mass spectrometry for emergency toxicology, where time is often of the essence for receiving the analysis. Some work in this area has already been done. Looking even further into the future, one might envision the small bedside mass spectrometer in hospitals. Driving the field toward on-site mass spectrometers is not just miniaturization of the MS analyzers but also the development of new (so-called ambient) ion sources such as DESI and paper spray.

Imaging by mass spectrometry is rapidly developing at the R&D level. A potential advantage here is that the image can be specific for single analytes or specific to classes of analytes, and if the image is acquired in full mass spectrum mode the images at each *m/z* provides complementary chemical information in the images. One can think about this as being analogous to images acquired by histopathological staining methods, except that the MS-based imaging is potentially far more information-rich.

Overall, there are many potential exciting applications of mass spectrometry in clinical diagnostics. Taking advantage of these opportunities and implementing mass spectrometry are not necessarily straightforward. This book provides practical guidance to help more laboratories adopt this technology.

Overview of the Book Design

This book provides a comprehensive and practical guide to implementing liquid chromatography–mass spectrometry (LC-MS/MS) in clinical laboratories. It is designed for laboratory professionals, clinical chemists, and researchers who are either currently using or planning to adopt mass spectrometry for clinical applications.

The book begins with an introduction that offers essential background on mass spectrometry, including a brief history of the technology, its advantages in clinical laboratories, and the types of analytes it can measure. This section also addresses common challenges and limitations associated with LC-MS/MS implementation.

The core content of the book starts with *Fundamentals of Mass Spectrometry*, covering key principles such as ionization techniques, mass analyzers, and detectors. This chapter provides best practices for utilizing mass spectrometry to generate accurate and reliable patient results. Following this, the *Fundamentals of Liquid Chromatography* chapter introduces the principles and components of liquid chromatography, explaining how it supports mass spectrometry analysis.

A critical step in LC-MS/MS workflows is sample preparation, which is detailed in the *Sample Preparation for LC-MS/MS Analysis* chapter. This chapter offers practical strategies to optimize sample handling and preparation, ensuring precision and reproducibility. Next, the book explores *Specific Laboratory Techniques for*

LC-MS/MS Analysis, sharing expert insights and hands-on guidance to help laboratories avoid common pitfalls when developing assays.

With a strong foundation established, the book then delves into *Method Development and Validation*, providing a step-by-step approach to designing, optimizing, and validating LC-MS/MS assays to meet clinical and regulatory standards.

Once assays are developed, ongoing maintenance is critical to sustaining high-quality results. The *Instrument and Assay Maintenance* chapter outlines best practices for maintaining and servicing mass spectrometry instruments, including routine upkeep and troubleshooting strategies. This is followed by *Troubleshooting for LC-MS/MS Assays*, which offers expert approaches to diagnosing and resolving issues to ensure assay performance and reliability.

Interpreting mass spectrometry data is an essential skill, and *Data Analytics* provides foundational knowledge on processing, interpreting, and visualizing LC-MS/MS results.

To ensure accuracy and reliability in patient testing, a strong quality assurance program is necessary. *Quality Assurance for LC-MS/MS Assays* discusses quality control measures and best practices for maintaining robust assay performance.

Finally, the book addresses regulatory considerations in *Regulations and Laboratory-Developed Tests (LDTs) for LC-MS/MS Assays*. This chapter provides guidance on navigating regulatory requirements and compliance considerations for LC-MS/MS-based clinical tests.

Our goal is to provide practical guidance to those implementing LC-MS/MS in clinical laboratories to enhance patient care. The adoption of this technology is complex, requiring years of expertise and dedicated effort to ensure success. By sharing the collective experience of leaders in the field, this book aims to bridge knowledge gaps and support laboratories in leveraging LC-MS/MS for high-quality, patient-centered diagnostics. We hope that readers will gain the knowledge and confidence needed to successfully implement and optimize LC-MS/MS in their laboratories.

References

1. Ettre LS, Sakodynskii KIMS. Tswett and the discovery of chromatography I: early work (1899–1903). Chromatographia. 1993;35:223–31. https://doi.org/10.1007/BF02269707.
2. Novakova L, Vlckova H. A review of current trends and advances in modern bio-analytical methods: chromatography and sample preparation. Anal Chim Acta. 2009;656:8–35. https://doi.org/10.1016/j.aca.2009.10.004.
3. Robards K, Ryan D. Principles and practice of modern chromatographic methods. Elsevier Science & Technology; 2021.
4. Horvath CG, Preiss BA, Lipsky SR. Fast liquid chromatography: an investigation of operating parameters and the separation of nucleotides on pellicular ion exchangers. Anal Chem. 1967;39:1422–8. https://doi.org/10.1021/ac60256a003.
5. Colin H, Guiochon G. Introduction to reversed-phase high-performance liquid chromatography. J Chromatogr A. 1977;141:289–312. https://doi.org/10.1016/s0021-9673(00)93537-4.
6. Hirata Y, Novotny M. Techniques of capillary liquid chromatography. J Chromatogr A. 1979;186:521–8. https://doi.org/10.1016/s0021-9673(00)95272-5.

7. Novotny MV. Development of capillary liquid chromatography: a personal perspective. J Chromatogr A. 2017;1523:3–16. https://doi.org/10.1016/j.chroma.2017.06.042.
8. Jorgenson JW. Capillary liquid chromatography at ultrahigh pressures. Annu Rev Anal Chem. 2010;3:129–50. https://doi.org/10.1146/annurev.anchem.1.031207.113014.
9. Guillarme D, Schappler J, Rudaz S, Veuthey J-L. Coupling ultra-high-pressure liquid chromatography with mass spectrometry. TrAC Trends Anal Chem (Regular ed.). 2010;29:15–27. https://doi.org/10.1016/j.trac.2009.09.008.
10. Budzikiewicz H, Grigsby RD. Mass spectrometry and isotopes: a century of research and discussion. Mass Spectrom Rev. 2006;25:146–57. https://doi.org/10.1002/mas.20061.
11. Griffiths IWJJ. Thomson – the centenary of his discovery of the electron and of his invention of mass spectrometry. Rapid Commun Mass Spectrom. 1997;11:2–16. https://doi.org/10.1002/(SICI)1097-0231(19970115)11:1<2::AID-RCM768>3.0.CO;2-V.
12. Munro, G. C. The theory of the modified Aston-type mass-spectrometer, (1933).
13. Aston FW. Mass-spectra and the atomic weights of the elements. Sci Prog Twent Century (1919–1933). 1920;15:212–22.
14. Cotter RJ. Time-of-flight mass spectrometry for the structural analysis of biological molecules. Anal Chem (Washington). 1992;64:1027A–39A. https://doi.org/10.1021/ac00045a002.
15. Mamyrin BA. Time-of-flight mass spectrometry (concepts, achievements, and prospects). Int J Mass Spectrom. 2001;206:251–66. https://doi.org/10.1016/S1387-3806(00)00392-4.
16. Finnigan RE. Quadrupole mass spectrometers. Anal Chem (Washington). 1994;66:969A–75A. https://doi.org/10.1021/ac00091a002.
17. Dawson PH. Quadrupole mass spectrometry and its applications. Elsevier Scientific Pub. Co.; 1976.
18. Cooks RG, Glish GL, McLuckey SA, Kaiser RE. Ion trap mass spectrometry. Chem Eng News. 1991;69:26–41. https://doi.org/10.1021/cen-v069n012.p026.
19. March RE. An introduction to quadrupole ion trap mass spectrometry. J Mass Spectrom. 1997;32:351–69. https://doi.org/10.1002/(SICI)1096-9888(199704)32:4<351::AID-JMS512>3.3.CO;2-P.
20. Fenn JB, Mann M, Meng CK, Wong SF, Whitehouse CM. Electrospray ionization for mass spectrometry of large biomolecules. Science. 1989;246:64–71. https://doi.org/10.1126/science.2675315.
21. Fenn JB, Mann M, Meng CK, Wong SF, Whitehouse CM. Electrospray ionization-principles and practice. Mass Spectrom Rev. 1990;9:37–70. https://doi.org/10.1002/mas.1280090103.
22. Sekiya S, Wada Y, Tanaka K. Derivatization for stabilizing sialic acids in MALDI-MS. Anal Chem (Washington). 2005;77:4962–8. https://doi.org/10.1021/ac050287o.
23. Berkenkamp S, Kirpekar F, Hillenkamp F. Infrared MALDI mass spectrometry of large nucleic acids. Science. 1998;281:260–2. https://doi.org/10.1126/science.281.5374.260.
24. Hillenkamp, F. & Peter-Katalinić, J. MALDI MS: a practical guide to instrumentation, methods and applications. (2007).
25. Bahr U, Karas M, Hillenkamp F. Analysis of biopolymers by matrix-assisted laser desorption/ionization (MALDI) mass spectrometry. Fresenius J Anal Chem. 1994;348:783–91. https://doi.org/10.1007/BF01780979.
26. Zytkovicz TH, et al. Tandem mass spectrometric analysis for amino, organic, and fatty acid disorders in newborn dried blood spots: a two-year summary from the New England newborn screening program. Clin Chem (Baltimore, Md.). 2001;47:1945–55.
27. Rashed MS, Ozand PT, Bucknall MP, Little D. Diagnosis of inborn errors of metabolism from blood spots by acylcarnitines and amino acids profiling using automated electrospray tandem mass spectrometry. Pediatr Res. 1995;38:324–31. https://doi.org/10.1203/00006450-199509000-00009.
28. Covey TR, Lee ED, Bruins AP, Henion JD. Liquid chromatography/mass spectrometry. Anal Chem (Washington). 1986;58:1451A–61A. https://doi.org/10.1021/ac00127a001.
29. Pitt JJ. Principles and applications of liquid chromatography-mass spectrometry in clinical biochemistry. Clin Biochem Rev. 2009;30:19–34.

30. Pesce A, et al. An evaluation of the diagnostic accuracy of liquid chromatography-tandem mass spectrometry versus immunoassay drug testing in pain patients. Pain Physician. 2010;13:273–81.
31. Maralikova B, Weinmann W. Confirmatory analysis for drugs of abuse in plasma and urine by high-performance liquid chromatography–tandem mass spectrometry with respect to criteria for compound identification. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;811:21–30. https://doi.org/10.1016/j.jchromb.2004.04.039.
32. Fitzgerald RL, Rivera JD, Herold DA. Broad spectrum drug identification directly from urine, using liquid chromatography-tandem mass spectrometry. Clin Chem (Baltimore, Md.). 1999;45:1224–34. https://doi.org/10.1093/clinchem/45.8.1224.
33. Dams R, Murphy CM, Lambert WE, Huestis MA. Urine drug testing for opioids, cocaine, and metabolites by direct injection liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2003;17:1665–70. https://doi.org/10.1002/rcm.1098.
34. Henion JD. Drug analysis by continuously monitored liquid chromatography/mass spectrometry with a quadrupole mass spectrometer. Anal Chem (Washington). 1978;50:1687–93. https://doi.org/10.1021/ac50034a029.
35. Taylor PJ, Tai C-H, Franklin ME, Pillans PI. The current role of liquid chromatography-tandem mass spectrometry in therapeutic drug monitoring of immunosuppressant and antiretroviral drugs: mass spectrometry in laboratory medicine. Clin Biochem. 2011;44:14–20.
36. Taylor PJ. Therapeutic drug monitoring of immunosuppressant drugs by high-performance liquid chromatography-mass spectrometry. Ther Drug Monit. 2004;26:215–9. https://doi.org/10.1097/00007691-200404000-00023.
37. McShane AJ, Bunch DR, Wang S. Therapeutic drug monitoring of immunosuppressants by liquid chromatography–mass spectrometry. Clin Chim Acta. 2016;454:1–5. https://doi.org/10.1016/j.cca.2015.12.027.
38. Kushnir MM, et al. Liquid chromatography tandem mass spectrometry for analysis of steroids in clinical laboratories: mass spectrometry in laboratory medicine. Clin Biochem. 2011;44:77–88.
39. Vogeser M, Parhofer KG. Liquid chromatography tandem-mass spectrometry (LC-MS/MS)—technique and applications in endocrinology. Exp Clin Endocrinol Diabetes. 2007;115:559–70. https://doi.org/10.1055/s-2007-981458.
40. Kushnir MM, Rockwood AL, Bergquist J. Liquid chromatography-tandem mass spectrometry applications in endocrinology. Mass Spectrom Rev. 2010;29:480–502. https://doi.org/10.1002/mas.20264.
41. Siekmann L, Hoppen H-O, Breuer H. Determination of steroid hormones in body fluids by gas chromatography-mass spectrometry, using a multiple ion detector. Anal Bioanal Chem. 1970;252:294–8.
42. Chapman JR, Bailey E. Determination of plasma testosterone by combined gas chromatography-mass spectrometry. J Chromatogr A. 1974;89:215–24. https://doi.org/10.1016/S0021-9673(01)99396-3.
43. Dehennin L, Reiffsteck A, Scholler R. A quantitative method for the estimation of testosterone and progesterone in human plasma, using the gas chromatograph/mass spectrometer combination with single ion monitoring. J Steroid Biochem. 1974;5:81–6. https://doi.org/10.1016/0022-4731(74)90032-6.
44. Björkhem I, Lantto O, Svensson L. Serum testosterone determination by mass fragmentography. Clin Chim Acta. 1975;60:59–66. https://doi.org/10.1016/0009-8981(75)90180-1.
45. Siekmann L. Determination of steroid hormones by the use of isotope dilution--mass spectrometry: a definitive method in clinical chemistry. J Steroid Biochem. 1979;11:117–23. https://doi.org/10.1016/0022-4731(79)90285-1.
46. Finlay EM, Gaskell SJ. Determination of testosterone in plasma from men by gas chromatography/mass spectrometry, with high-resolution selected-ion monitoring and metastable peak monitoring. Clin Chem. 1981;27:1165–70.
47. Salerno R, et al. Simultaneous determination of testosterone, dihydrotestosterone and 5 alpha-androstan-3 alpha,-17 beta-diol by isotopic dilution mass spectrometry in plasma and prostatic

tissue of patients affected by benign prostatic hyperplasia. Effects of 3-month treatment with a GnRH analog. J Androl. 1988;9:234–40. https://doi.org/10.1002/j.1939-4640.1988.tb01043.x.
48. Furuta T, Kusano K, Kasuya Y. Simultaneous measurements of endogenous and deuterium-labelled tracer variants of androstenedione and testosterone by capillary gas chromatography-mass spectrometry. J Chromatogr. 1990;525:15–23. https://doi.org/10.1016/s0378-4347(00)83376-9.
49. Legrand C, Dousset B, Tronel H, Belleville F, Nabet P. Measurement of plasma testosterone by gas chromatography-negative-ion mass spectrometry using pentafluoropropionic derivatives. J Chromatogr B Biomed Appl. 1995;663:187–92. https://doi.org/10.1016/0378-4347(94)00461-d.
50. Fitzgerald RL, Herold DA. Serum total testosterone: immunoassay compared with negative chemical ionization gas chromatography-mass spectrometry. Clin Chem. 1996;42:749–55.
51. Wians FH Jr, Stuart J. Ciba corning ACS:180 direct total testosterone assay can be used on female sera. Clin Chem. 1997;43:1466–8.
52. Fitzgerald RL, Herold DA. Ciba corning ACS:180 direct total testosterone assay can be used on female sera: reply. Clin Chem. 1997;43:1467–8.
53. Stanczyk FZ. Reliability of extraction/chromatography RIAs. Clin Chem. 2004;50:778. https://doi.org/10.1373/clinchem.2004.031492.
54. Herold DA, Fitzgerald RL. Reliability of extraction/chromatography RIAs: response. Clin Chem. 2004;50:778. https://doi.org/10.1373/clinchem.2004.032128.
55. Stanczyk FZ. Extraction/chromatographic testosterone RIA can be used as the "gold standard" for determining the reliability of direct testosterone immunoassay measurements. Clin Chem. 2004;50:2219–2220; author reply 2220–2211. https://doi.org/10.1373/clinchem.2004.038505.
56. Taieb J, et al. Testosterone measured by 10 immunoassays and by isotope-dilution gas chromatography-mass spectrometry in sera from 116 men, women, and children. Clin Chem. 2003;49:1381–95. https://doi.org/10.1373/49.8.1381.
57. Herold DA, Fitzgerald RL. Immunoassays for testosterone in women: better than a guess? Clin Chem. 2003;49:1250–1. https://doi.org/10.1373/49.8.1250.
58. Zhang YV, Rockwood A. Impact of automation on mass spectrometry. Clin Chim Acta. 2015;450:298–303. https://doi.org/10.1016/j.cca.2015.08.027.
59. Salvagno GL, Danese E, Lippi G. Mass spectrometry and total laboratory automation: opportunities and drawbacks. Clin Chem Lab Med. 2020;58:994–1001. https://doi.org/10.1515/cclm-2019-0723.
60. Gqamana PP, Militello L, McMaster JM, Daley SJ, Zhang YV. Analytical concordance of total vitamin D on a fully automated random-access LC–MS/MS platform. J Appl Lab Med. 2023;8:940–51. https://doi.org/10.1093/jalm/jfad036.
61. Mathieu E, Duterme C, Fage D, Cotton F. Cascadion™ SM clinical analyzer: evaluation of the whole blood immunosuppressants quantification and routine usability. Clin Chim Acta. 2023;539:97–104. https://doi.org/10.1016/j.cca.2022.11.029.

Fundamentals of Mass Spectrometry

2

Cody Orahoske, Hanna Lusk, Shanel C. Pickard, and Alan H. B. Wu

Introduction

The history of mass spectrometry (MS) dates back to the turn of the twentieth century when physicist John Thomson and his team constructed an instrument that could measure mass as a ratio of charge [1]. During the first few decades, most of the work involving mass spectrometry was conducted on isotope research of elements. These studies were important in the Manhattan Project, where ^{235}uranium and ^{239}plutonium were combined to produce the first atomic bomb. Chemists initially utilized this powerful new tool to determine the structures of newly synthesized organic compounds, but its application was limited to pure samples or simple, well-characterized mixtures. This changed in the early 1950s when Fred McLafferty and Roland Gohlke, then of Dow Chemical Co., coupled gas chromatography (GC) as a means of separation of complex mixtures and thereby greatly expanded MS as a detection method for unknown compounds [2]. Within a few years, GC/MS was adopted into routine clinical practice, especially for qualitative urine drug confirmations and later for quantitative therapeutic drug monitoring [3]. The utility of GC–MS, however, was primarily limited to small, non-volatile compounds and required a laborious pre-analytical step involving chemical derivatization to render them volatile compounds suitable for analysis.

The more widespread clinical implementation of mass spectrometry came in the 1980s, with several key developments significantly expanding its capabilities. First, the

C. Orahoske
Department of Laboratory Medicine, University of California, San Francisco, CA, USA

Lab Corp, Calabasas, CA, USA
e-mail: cody.orahoske@labcorp.com

H. Lusk · S. C. Pickard · A. H. B. Wu (✉)
Department of Laboratory Medicine, University of California, San Francisco, CA, USA
e-mail: hanna.lusk@ucsf.edu; shanel.pickard@ucsf.edu; alan.wu@ucsf.edu

Y. V. Zhang, U. Garg (eds.), *Practical Guide to Implementing Liquid Chromatography Mass Spectrometry in Clinical Laboratories*,
https://doi.org/10.1007/978-3-032-03852-4_2

development of soft ionization techniques, particularly electrospray ionization (ESI) and matrix-assisted laser desorption/ionization (MALDI), made it possible to analyze large biomolecules like proteins and peptides without the excessive fragmentation caused by hard ionization methods. Equally important, these novel ionization techniques expanded the sample types that could be compatible with mass spectrometry; ESI allowed for liquid-phase samples to be directly introduced into the mass spectrometer, eliminating the need to volatilize the sample and making it feasible to interface liquid chromatography as a pre-analytical step to efficiently separate unknown liquid mixtures [4]. In contrast, MALDI uses laser energy to ionize solid-phase samples, allowing for the direct analysis of crystallized specimens [5]. The impact of these ionization techniques was recognized by awarding the 2002 Nobel Prize in Chemistry to John Fenn, Koichi Tanaka, and Kurt Wüthrich for their contributions.

Clinical laboratories have long relied on immunoassays as the gold standard for hormone analysis, therapeutic drug monitoring, and biomarker detection. While effective, immunoassays inherently suffer from cross-reactivity, particularly in steroid hormone analysis and drug screening [6]. Furthermore, the immunoassays rely on the isolation of high-affinity antibodies through a scalable process to make commercial kits feasible and cost-effective. In other words, developing an assay for each target analyte is a process engineering challenge—ultimately limiting which analytes can be affordably targeted. Conversely, MS does not rely on affinity-based targeting paradigms. It uses unique mass-to-charge (m/z) signatures to identify and quantify analytes, thus allowing MS to distinguish between structurally similar compounds with high accuracy. Liquid chromatography–tandem mass spectrometry (LC-MS/MS) emerged in the 1990s that combines liquid chromatography for analyte separation with tandem mass spectrometry for highly specific identification and quantification. The tandem mass spectrometers work sequentially, with the first MS selecting for precursor ions of interest based on their mass-to-charge (m/z) ratio. Collision-induced dissociation (CID) or other fragmentation techniques further break the precursor ions to product ions that feed into the second MS for detection, making these systems a powerful alternative to immunoassays in complex biological matrices. In the microbiology laboratory, MALDI-TOF MS has revolutionized microbiology, replacing time-consuming culture-based identification methods with rapid microbial detection in minutes.

Additionally, improvements in mass analyzers—such as quadrupoles, time-of-flight (TOF), and Orbitraps—enhanced sensitivity and specificity, making MS more reliable for clinical diagnostics. These technological advancements positioned MS as an attractive alternative to traditional clinical methods, which often struggled with specificity, sensitivity, and turnaround time. For example, immunoassays, a mainstay in clinical testing, suffer from cross-reactivity, leading to inaccurate hormone and drug measurements. Similarly, conventional microbiological culture methods require extended incubation periods, whereas MALDI-TOF MS can identify pathogens in minutes. As a result, mass spectrometry emerged as a powerful solution to fill these critical gaps, offering precise, high-throughput analysis for modern clinical laboratories.

While mass spectrometry has addressed many limitations of traditional techniques—and, in some cases, replaced them—full reliance on MS in clinical laboratories still faces challenges. The technique lacks full automation and requires

expertise for data interpretation and method development [3]. Standardization across laboratories remains an ongoing challenge, with regulatory bodies providing slow guidance on appropriate compliance and quality control measures. Despite these challenges, MS continues to have an expanding role in diagnostics across the spectrum of human disease. Advancements in automation, miniaturization, and bioinformatics will further solidify it in the modern clinical laboratory.

Basic Components and Concepts

While modern mass spectrometry workflows can be highly complex, the core analysis relies on three main components: the ion source, mass analyzer, and detector, each playing a crucial role in the identification and quantification of analytes. Figure 2.1 shows a prototypical MS workflow, including example pre-analytical



Fig. 2.1 A schematic of a typical mass spectrometry process flow, illustrating key steps from sample preparation to data analysis (1). A biological sample (e.g., blood) is collected and processed (2). The sample undergoes chromatographic separation via chromatography, such as liquid chromatography (LC) or gas chromatography (GC) to better separate constituents of the mixture (3). The analytes are ionized which can be done with varying types of ionization techniques, such as electrospray ionization (ESI), matrix-assisted laser desorption/ionization (MALDI), atmospheric pressure chemical ionization (APCI), or atmospheric pressure photoionization (APPI) (4). The mass analyzer separates ions based on their mass-to-charge ratio (m/z), using instruments such as quadrupole (Q, triple quadrupole: QqQ), time-of-flight (TOF, quadrupole-TOF: Q-TOF), Orbitrap, or Fourier transform ion cyclotron resonance (FTICR) (5). The ions are detected using devices like an electron multiplier or Faraday cup (6). The resulting mass spectrum displays the detected m/z values, enabling analyte identification and quantification

Table 2.1 High-level comparison of LC-MS and GC–MS, highlighting key differences in sample compatibility, ionization techniques, and analytical applications

	LC-MS		GC–MS	
Mobile phase	Liquid		Inert gas	
Ionization methods	Soft ionization techniques [11]: ESI APCI		Hard ionization techniques [11]: EI CI	
Applications	Non-volatile Thermally labile Polar Large (proteins and peptides) [11] Metabolic [12]	Qualitative [11] Quantitative [11]	Volatile Thermally stable Non-polar Small organic molecules Forensic toxicology	Qualitative [11] Quantitative [11]
Throughput	Slower		Faster	
Automation Capabilities	High [11]		Low-moderate [11]	

steps that may be incorporated into the processing of a sample. For example, patient samples may undergo extraction and dilution depending on the matrix; enrichment aims to increase the concentration of target analytes while minimizing matrix interference to improve sensitivity in subsequent steps (Fig. 2.1, step 1). Chromatography (Fig. 2.1, step 2) further refines the sample by separating complex mixtures such that the various constituents enter the mass spectrometer at distinct times. While a separate chapter is dedicated to chromatography, a brief table comparing LC-MS and GC–MS is provided here primarily to offer a high-level overview of their key differences in sample compatibility, ionization methods, and analytical applications (Table 2.1). Of interest to the remainder of this section is an overview of the spectrometer's core components and a review of high-yield concepts that will help the reader to better appreciate distinctions made between the compared technologies (see Table 2.2 for key definitions that will be seen in this chapter).

Ion Sources

The ion source is the first critical component of the mass spectrometer and is responsible for converting neutral molecules into charged ions, as subsequent MS steps rely on using charge to differentiate species and isolate targets (Fig. 2.1, step 3). In this configuration of LC-MS/MS, the eluent coming from the chromatography separation is in the liquid phase as it reaches the ion source. Due to this, the source must be able to convert the liquid into a gas phase to allow for the ions to travel into the mass analyzer. As far as clinical mass spectroscopy, atmospheric pressure ionization (API) is the predominant ion source type, which can be further subdivided into three different classifications: electrospray ionization (ESI), atmospheric pressure chemical ionization (APCI), and atmospheric pressure photoionization (APPI) [1, 2].

Table 2.2 Key mass spectrometry definitions

Concept	Component	Definition
Isotope	–	Variants of an element with the same number of protons but different numbers of neutrons
Ion	Ionizer	A charged particle formed when a molecule gains or loses electrons during ionization
Mass-to-charge ratio (m/z)	Analyzer	Fundamental measurement used to differentiate ions based on their charge state
Resolution	Analyzer	The degree by which two closely spaced peaks in a spectrum can be distinguish with less than a defined overlap [7–9].
Resolving power	Analyzer	"Ability to distinguish between peaks differing in the m/z by an increment $\Delta(m/z)$ given by $(m/z)/\Delta(m/z)$. The value of $\Delta(m/z)$ is obtained from the peak width at a specified fraction of the peak height or from the valley between two peaks of specified height" [9, 10]
Accurate mass	Analyzer	The deviation between the measured and actual mass [8]
Mass range	Analyzer	The span of m/z values that the analyzer can detect [9]
Fragmentation	Analyzer	The process where precursor ions break apart into two or more fragment, and at least one fragment is an ion [9]
Mass spectrum	Detector	Graphical representation of detected ions, displaying their mass-to-charge ratio (m/z) on the x-axis and relative abundance on the y-axis [9]
Isotope patterns	Detector	A series of peaks of relative abundance of ions with the same chemical formula but different isotopic composition [9]
Deconvolution	Analysis	A computational method used to resolve overlapping peaks in a mass spectrum [9]

This table outlines essential concepts in mass spectrometry, categorizing them by their corresponding components and definitions

More recently, research has explored ionization techniques that eliminate the need for LC, allowing direct ionization of the sample into the mass spectrometer. Matrix-assisted laser Desorption/Ionization (MALDI) has become an integrated instrument within microbiology for the identification of bacterial cultures [3]. Newer ionization methods in the past two decades belong to a class of ionization sources called ambient ionization mass spectrometry (AIMS), some highlighted, coated blade spray (CBS), desorption electrospray ionization (DESI), direct analysis in real time (DART), and rapid evaporative ionization mass spectrometry (REIMS) [4–7].

Electrospray Ionization

As the field of clinical mass spectrometry matures, one of the most widely used ion sources belongs to ESI [6, 8–10]. The technique involves applying a high voltage to a flowing stream of liquid eluent, which results in the production of a fine mist of charged droplets at atmospheric pressure [10, 11]. These droplets undergo gradual

T